DK2366400T3 - Fremgangsmåde til behandling af patienter med en mucinøs glycoprotein (MUC-1) -vaccine - Google Patents

Fremgangsmåde til behandling af patienter med en mucinøs glycoprotein (MUC-1) -vaccine Download PDF

Info

Publication number
DK2366400T3
DK2366400T3 DK10191602.1T DK10191602T DK2366400T3 DK 2366400 T3 DK2366400 T3 DK 2366400T3 DK 10191602 T DK10191602 T DK 10191602T DK 2366400 T3 DK2366400 T3 DK 2366400T3
Authority
DK
Denmark
Prior art keywords
muc
treatment
weeks
patients
nsclc
Prior art date
Application number
DK10191602.1T
Other languages
English (en)
Inventor
Michael B Longenecker
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Application granted granted Critical
Publication of DK2366400T3 publication Critical patent/DK2366400T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Claims (13)

1. MUC-l-baseret vaccineformulering omfattende et liposom omfattende en MUC-1-kernegentagelse med en aminosyresekvens som er mindst 80% identisk med SEQ ID NO:2 til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) i et individ, behandlingen omfattende: (a) at måle niveauet af cirkulerende tumormarkør CA27.29 (MUC-1) med enzym-koblet immunosorbent-, chemiluminescent- eller radioimmunoassay i et individ med en cancercelle som udtrykker MUC-1; (b) at vælge til behandling et individ med et cirkulerende CA27.29 (MUC-1) -niveau på 37,7 U/ml eller mindre; og (c) at administrere til individet, for en tidsperiode, den MUC-l-baserede formulering.
2. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 1, hvor formuleringen yderligere omfatter mindst en adjuvans valgt fra gruppen bestående af lipid A, muramyl dipeptid, alun, et cytokin, og en kombination deraf.
3. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 2, hvor lipid A er monophosphoryl lipid A eller et syntetisk lipid A.
4. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 1, yderligere omfattende et trin (d) at evaluere det behandlede individ.
5. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 4, hvor at evaluere det behandlede individ udføres: (i) før tidsperioden fortrin (c); (ii) undertidsperioden fortrin (c); (iii) efter tidsperioden for trin (c); eller (iv) en kombination deraf.
6. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 4 eller 5, hvor at evaluere det behandlede individ omfatter at måle en immunreaktion i det behandlede individ.
7. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 6, hvor at måle immunreaktionen i det behandlede individ omfatter at måle en T-celle proliferation.
8. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 1, hvor liposomvaccinen er tilvejebragt i et kit.
9. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge et hvilket som helst af kravene 1 til 8, hvor trinnet til administration er ved injektion-, aerosol-, nasal-, vaginal-, rektal-, kind-, øje-, lokal-, topisk-, intracisternal-, intraperitoneal-, eller oral indgivelse, og hvor injektionen er en intramuskulær, intravenøs, subkutan, intranodal, intratumoral, intraperitoneal, eller intradermal injektion.
10. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge et hvilket som helst af kravene 1 til 9, hvor tidsperioden er valgt fra gruppen bestående af mindst omkring 2 uger, mindst omkring 4 uger, mindst omkring 8 uger, mindst omkring 16 uger, mindst omkring 17 uger, mindst omkring 18 uger, mindst omkring 19 uger, mindst omkring 20 uger, mindst omkring 24 uger, mindst omkring 28 uger, mindst omkring 32 uger, mindst omkring 36 uger, mindst omkring 40 uger, mindst omkring 44 uger, mindst omkring 48 uger, mindst omkring 52 uger, mindst omkring 60 uger, mindst omkring 68 uger, mindst omkring 72 uger, mindst omkring 80 uger, mindst omkring 88 uger, mindst omkring 96 uger, og mindst omkring 104 uger.
11. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge et hvilket som helst af kravene 1 til 10, hvor individet behandles med cyclophosphamid forud for (c).
12. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 1, hvor liposomvaccinen omfatter omkring 300 pg af et MUC-l-peptid.
13. MUC-l-baseret formulering til anvendelse i behandling af ikke-småcellet lungekræft (NSCLC) ifølge krav 1, hvor liposomvaccinen omfatter omkring 1000 pg af et MUC-l-peptid.
DK10191602.1T 2005-06-28 2006-06-27 Fremgangsmåde til behandling af patienter med en mucinøs glycoprotein (MUC-1) -vaccine DK2366400T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69423305P 2005-06-28 2005-06-28
EP06808953.1A EP1896051B1 (en) 2005-06-28 2006-06-27 Method of treating patients with a mucinous glycoprotein (muc-1) vaccine

Publications (1)

Publication Number Publication Date
DK2366400T3 true DK2366400T3 (da) 2016-01-11

Family

ID=37708986

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10191602.1T DK2366400T3 (da) 2005-06-28 2006-06-27 Fremgangsmåde til behandling af patienter med en mucinøs glycoprotein (MUC-1) -vaccine
DK06808953T DK1896051T3 (da) 2005-06-28 2006-06-27 Fremgangsmåde til behandling af patienter med en mucinøs glycoprotein (muc-1)-vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06808953T DK1896051T3 (da) 2005-06-28 2006-06-27 Fremgangsmåde til behandling af patienter med en mucinøs glycoprotein (muc-1)-vaccine

Country Status (16)

Country Link
US (3) US8871250B2 (da)
EP (2) EP2366400B1 (da)
JP (3) JP5364371B2 (da)
CN (2) CN105194650A (da)
AR (1) AR054526A1 (da)
AU (1) AU2006274651B2 (da)
BR (1) BRPI0613510A2 (da)
CA (1) CA2613327A1 (da)
DK (2) DK2366400T3 (da)
ES (2) ES2526344T3 (da)
HK (1) HK1219417A1 (da)
HU (1) HUE026490T2 (da)
PL (2) PL2366400T3 (da)
PT (2) PT1896051E (da)
TW (2) TWI511738B (da)
WO (1) WO2007015171A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
JP5364371B2 (ja) * 2005-06-28 2013-12-11 オンコセリオン インコーポレイテッド ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
CN102256595A (zh) * 2008-12-17 2011-11-23 肿瘤防护公司 制备小粒径脂质体的方法
WO2010108908A1 (en) * 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
JP5661738B2 (ja) * 2009-04-17 2015-01-28 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者をモニターするためのバイオマーカー
GB0910751D0 (en) * 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
EP2560989B1 (en) 2010-04-19 2017-03-22 Sumitomo Bakelite Co., Ltd. Cancer-related glycopeptide epitopes, antibodies and methods of use
CN105193724A (zh) 2011-02-24 2015-12-30 肿瘤防护公司 含有佐剂的以muc1 为基础的糖脂肽疫苗
CN105283199A (zh) * 2013-05-14 2016-01-27 默克专利股份公司 通过muc-1脂肽接种治疗肺癌的方法
CN105517566A (zh) * 2013-08-21 2016-04-20 库瑞瓦格股份公司 用于治疗前列腺癌的组合物和疫苗
US9467478B1 (en) 2013-12-18 2016-10-11 vIPtela Inc. Overlay management protocol for secure routing based on an overlay network
WO2015099224A1 (ko) 2013-12-26 2015-07-02 주식회사 포스코 압연장치, 연주압연장치 및 방법
US11433143B2 (en) 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CN112190688A (zh) * 2020-09-09 2021-01-08 广州医科大学附属第一医院（广州呼吸中心） 粘蛋白muc1在制备具有延缓肺衰老功效的药物中的应用
WO2026011417A1 (en) * 2024-07-12 2026-01-15 The Hong Kong University Of Science And Technology Compositions and methods involving artificial poly (a) sequences

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
DE3683688D1 (de) 1985-04-19 1992-03-12 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1996040236A1 (en) 1995-06-07 1996-12-19 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU734253B2 (en) 1996-03-20 2001-06-07 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
ATE273320T1 (de) 1996-04-11 2004-08-15 Univ British Columbia Fusogene liposomen
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
JP4480800B2 (ja) 1997-05-08 2010-06-16 オンコシリオン・インコーポレイテッド 活性化ｔ細胞および抗原パルス標識した抗原提示細胞を生成する方法
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
DE60018761T2 (de) 1999-08-18 2006-02-02 Altarex Medical Corp., Edmonton Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
AU780577B2 (en) 1999-11-15 2005-04-07 Oncothyreon Inc. Synthetic Lipid-A analogs and uses thereof
WO2001070265A2 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
AU1999802A (en) 2000-12-01 2002-06-11 Lawrence Boni Preparation of large liposomes by infusion into peg
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
EP2263465A1 (en) 2001-07-06 2010-12-22 Sloan-Kettering Institute for Cancer Research Polyvalent conjugate vaccine for cancer
US20060069238A1 (en) 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
ATE457733T1 (de) 2002-05-09 2010-03-15 Oncothyreon Inc Lipid-a- und andere kohlenhydrat-liganden-analoga
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
JP5364371B2 (ja) 2005-06-28 2013-12-11 オンコセリオン インコーポレイテッド ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法

Also Published As

Publication number Publication date
AR054526A1 (es) 2007-06-27
TWI511738B (zh) 2015-12-11
TW200738253A (en) 2007-10-16
JP2016014046A (ja) 2016-01-28
PT2366400E (pt) 2016-02-02
US20070014844A1 (en) 2007-01-18
JP2008546833A (ja) 2008-12-25
HUE026490T2 (en) 2016-06-28
US9119784B2 (en) 2015-09-01
CN101309697A (zh) 2008-11-19
JP5364371B2 (ja) 2013-12-11
EP2366400A1 (en) 2011-09-21
CA2613327A1 (en) 2007-02-08
JP5858894B2 (ja) 2016-02-10
ES2526344T3 (es) 2015-01-09
BRPI0613510A2 (pt) 2011-01-11
JP2013047234A (ja) 2013-03-07
PT1896051E (pt) 2015-01-13
DK1896051T3 (da) 2015-01-05
US20150071990A1 (en) 2015-03-12
US8871250B2 (en) 2014-10-28
ES2558131T3 (es) 2016-02-02
EP1896051A4 (en) 2008-08-27
WO2007015171A2 (en) 2007-02-08
WO2007015171A3 (en) 2007-06-14
CN105194650A (zh) 2015-12-30
EP1896051A2 (en) 2008-03-12
US20150359868A1 (en) 2015-12-17
AU2006274651A1 (en) 2007-02-08
EP1896051B1 (en) 2014-10-15
PL2366400T3 (pl) 2016-03-31
EP2366400B1 (en) 2015-09-30
HK1219417A1 (zh) 2017-04-07
PL1896051T3 (pl) 2015-04-30
TW201615208A (zh) 2016-05-01
AU2006274651B2 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
US9119784B2 (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
US20160082093A1 (en) Mucinous glycoprotein (muc-1) vaccine
AU2012268892B2 (en) Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine
HK1125842A (en) Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
HK1196071A (en) Mucinous glycoprotein(muc-1) vaccine